Mary Caffrey

Panelists at the leading health economics and outcomes conference discuss whether the FDA's process for allowing outside experts to weigh in on drug approvals needs changes.

The opening plenary session addresses a key priority of ISPOR on the first full day of the annual conference.

A CMS official discusses a draft guidance on the second round of drug pricing negotiations amid uncertainties over the first round of talks under the Inflation Reduction Act.

Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.

A panel discussion highlighted a new pathway that allows Medicare to embrace new tools and pay for them while gathering the evidence needed to ensure the technology is safe and appropriate for an older population.

The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas.

Pembrolizumab has existing indications in endometrial cancer.

The CEO of SCAN Health Plan discusses its first-ever Environmental, Social, and Governance Report.

Most older Ameri remain unaware of provisions of the Inflation Reduction Act that affect them, although awareness has increased.